- Daaweyn
- Markhaatiyada
- Neuroblastoma
- Buro adag
- Markhaatiyada
- TILS
- Daaweynta Unugyada NK
- Myasthenia Gravis (MG)
- Leukemia-da Lymphoblastic ee Ba'an (B-ALL)
- Lupus Erythematosus oo nidaamsan (SLE)
- Leukemia-da Lymphoblastic ee Ba'an (T-ALL)
- Lymphoma-ka aan Hodgkin ahayn (NHL)
- Myeloma badan (MM)
- Lymphom-ka Unugga B-B ee Kala-baxa
- Leukemia-da B-lymphocytic
- Myeloma
CAR-T oo loogu talagalay Glioblastoma
-
Unugga CAR-T
Daaweynta CAR-T (Chimeric Antigen Receptor T-cell) waxay u taagan tahay qaab casri ah oo ah daaweynta difaaca jirka. Waxay ku lug leedahay wax ka beddelka unugyadaada T - nooc ka mid ah unugyada difaaca jirka - si loo aqoonsado loona weeraro unugyada kansarka ee muujiya calaamado gaar ah. glioblastoma, daaweyntani waxay higsaneysaa inay bixiso daaweyn shaqsiyeed oo suurtogal ah inay dheereyso badbaadada oo yareyso calaamadaha, gaar ahaan marka lagu daro habab kale.
Bartilmaameedyada Daaweynta CAR-T ee Glioblastoma
Glioblastoma, borotiinno gaar ah oo ku yaal dusha sare ee unugyada burooyinka ayaa u adeega bartilmaameedyo ku habboon daaweynta CAR-T sababtoo ah muujinta xad-dhaafka ah ee unugyada kansarka iyo joogitaanka xaddidan ee unugyada caafimaadka qaba. Bioocus, waxaan diiradda saareynaa laba bartilmaameed oo muhiim ah:
- GD2: Kani waa antigen glycolipid ah oo caadi ahaan laga helo unugyada glioblastoma, iyo sidoo kale burooyinka kale ee maskaxda sida gliomas-ka dhexe ee kala firdhisan. GD2 wuxuu ku lug leeyahay calaamadaynta unugyada wuxuuna si aad ah ugu muuqdaa burooyinka gardarrada ah, taasoo ka dhigaysa calaamad rajo leh oo loogu talagalay bartilmaameedka difaaca jirka.
- B7-H3: Sidoo kale loo yaqaan CD276, borotiinkan isbaarada difaaca jirka ayaa aad loogu muujiyaa glioblastoma wuxuuna gacan ka geystaa ka fogaanshaha burooyinka ee nidaamka difaaca jirka. Waxay door ka ciyaartaa kor u qaadista kobaca kansarka iyo xakamaynta jawaabaha difaaca jirka, taasoo ka dhigaysa bartilmaameed wax ku ool ah oo lagu xoojinayo weerarrada unugyada T.
Iyada oo la adeegsanayo injineerinka unugyada CAR-T si loo aqoonsado GD2 ama B7-H3, daaweyntu waxay hagaysaa weerar diiradda lagu saarayo unugyada burooyinka iyadoo la yareynayo dhaawaca unugyada maskaxda ee caadiga ah.
Sida Daaweynta CAR-T u Shaqeyso: Habka Ficilka
Daaweynta CAR-T waxay ku bilaabataa ururinta muunad ka mid ah unugyadaada T iyada oo loo marayo hab la mid ah deeq-bixinta dhiigga. Unugyadan ayaa markaa hidde ahaan wax looga beddelaa shaybaar si ay u muujiyaan soo-dhoweeyaha antigen-ka ee chimeric (CAR) - soo-dhoweeye gaar ah oo u shaqeeya sida "qalab guri" oo loogu talagalay unugyada kansarka.
- Aqoonsiga: CAR-ka ku jira unugyada T wuxuu si gaar ah ugu xidhmaa GD2 ama B7-H3 unugyada glioblastoma, sida qufulka iyo furaha.
- Daar-gelintaMarka la xidho, CAR waxay kicisaa unugyada T inay firfircoonaadaan, tarmaan, oo ay sii daayaan molecules calaamadeysan oo kiciya unugyada kale ee difaaca jirka si ay ugu biiraan dagaalka.
- BurburUnugyada T ee firfircoon waxay si toos ah u weeraraan oo u dilaan unugyada kansarka ee la beegsanayo, taasoo keeni karta inay burooyinka yaraadaan oo ay yaraadaan culayska cudurka.
Hawshani waxay caadi ahaan ku lug leedahay in unugyada T-ga ee wax laga beddelay dib loogu shubo jirkaaga, badanaa iyada oo loo marayo habab gudbin xidid ama mid bartilmaameedsan si loo gaaro maskaxda. Hadafku waa in la abuuro jawaab celin difaac oo joogto ah oo sii wadata la socodka iyo baabi'inta unugyada kansarka ee harsan waqti ka dib.
Daaweynteena CAR-T waxay beegsaneysaa GD2 iyo B7-H3 ee Glioblastomamuuji waxtarka rajo leh ee tijaabooyinka caafimaad.
Loogu talagalay GD2 CAR-T, daraasad lagu sameeyay 37 bukaan oo qaba gliomas-ka heerka sare ah ee soo noqnoqda ama aan fiicnayn ayaa muujisay Heerka jawaab celinta ujeeddada ah 72%, oo leh 42% waxay gaaraan cafis dhammaystiran 6 toddobaad gudahood iyo 56% waxay ku hayaan 1.7 sano oo dabagal ah.
Wixii loogu talagalay B7-H3 CAR-T, tijaabo lagu sameeyay 39 qof oo qaangaar ah oo qaba glioblastoma soo noqnoqda ayaa lagu soo warramey a Heerka jawaab celinta 30–40% iyo Heerka xakamaynta cudurka 60–70%, oo leh badbaadada dhexdhexaadka ah ee 11 bilood (daaweyn hal mar ah) iyo 13.6 bilood (isku-darka), taasoo ka sarreysa xogta taariikhiga ah.
Labada daaweynba waa ammaan, oo leh waxyeellooyin fudud oo la maarayn karo. Bioocus waxay u heellan tahay horumarinta daawayntan cusub si loo hagaajiyo natiijooyinka bukaanada glioblastoma.
Daaweynta Shucaaca
Shucaaca Stereotactic (SRT) ama shucaaca jirka ee stereotactic (SBRT) waxaa lagu dari karaa CAR-T si loo bartilmaameedsado meelaha burooyinka, loo yareeyo cabbirka loona xoojiyo marin u helidda unugyada difaaca jirka. Habkan saxnaanta sare leh wuxuu yareeyaa dhaawaca unugyada caafimaadka qaba wuxuuna hagaajin karaa gelitaanka CAR-T.
Habraacyada Faragelinta
Ku-tallaalid walxaha Ku lug yeelashada walxaha shucaaca si toos ah loogu geliyo burooyinka si loogu helo shucaac ku meel gaar ah, iyadoo la dhammaystirayo CAR-T iyadoo la daciifinayo unugyada kansarka ka hor. Si loo helo marin u helidda maskaxda, Kaydka biyaha ee Ommaya meelaynta waxay u oggolaanaysaa in daawada si toos ah loogu geeyo dareeraha maskaxda, taasoo suurtogal ah inay kor u qaaddo qaybinta CAR-T.
Kaydka Ommaya
Qalabkan takhasuska leh, oo qalliin lagu geliyay madaxa hoostiisa, waxay u oggolaanaysaa in daawooyinka si toos ah loogu geeyo dareeraha maskaxda iyada oo loo marayo kateetar loo geliyo xididdada maskaxdaBukaannada glioblastoma, gaar ahaan kuwa qaba cudurka leptomeningeal, Kaydka Ommaya wuxuu suurtogal ka dhigayaa maamulka saxda ah ee unugyada CAR-T ama daawayn kale, hubinta uruurinta daawada oo sareysa ee habdhiska neerfaha dhexe iyadoo raaxo-darro yar la dareemayo marka la barbar dhigo daloolada dhabarka.
Istaraatiijiyadan qaababka badan leh waxay higsaneysaa inay ugu badnaan xakamaynta cudurka iyadoo la taageerayo soo kabashadaada iyo fayoobaantaada.
Su'aalaha Badiya La Weydiiyo
- Ma u qalmaa daaweynta CAR-T?U-qalmitaanku wuxuu ku xiran yahay arrimo ay ka mid yihiin nooca burooyinka, daawayntii hore, iyo caafimaadka guud. La-tashi lala yeesho khabiiradayada ayaa kaa caawin kara inaad go'aamiso inay kugu habboon tahay.
- Waa maxay waxyeellooyinka iman kara?Kuwa caadiga ah waxaa ka mid ah daalka, calaamadaha la xiriira bararka, iyo falcelinta difaaca jirka, kuwaas oo si dhow loola socdo loona maareeyo.
- Intee in le'eg ayuu hawshu qaadanaysaa?Laga bilaabo ururinta unugyada ilaa faleebo, waxay caadi ahaan socotaa dhowr toddobaad, iyadoo daryeelka dabagalka uu socdo.
Haddii aad ka fiirsaneyso Daaweynta CAR-T ee glioblastoma, waxaan halkaan u joognaa inaan ku taageerno daryeel naxariis leh oo ku salaysan caddayn. La xiriir kooxdeena Bioocus si aad u ballansato la-tashi iyo inaad barato sida habkan cusubi ugu habboonaan karo qorshahaaga daaweynta. Caafimaadkaaga iyo rajadaaduba way muhiim noo yihiin—aan si wadajir ah u sahamino fursadaha.
Submit An Free Inquiry
Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.